Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Pathos AI closed a $237 million Series E round at a post-money valuation of approximately $3 billion, led by Bristol Myers Squibb with participation from existing investors. Proceeds will scale the Foundry AI platform and fund a registrational study for JSKN016, a TROP2/HER3 bispecific ADC, plus advancement of pocenbrodib, AZD4241, and DO-2.
Key figures
- Deal Value Usd
- 237000000
- Financing round
- Series E
- Post money valuation
- $3 billion
- Clinical assets in pipeline
- 4
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.